Cetus Corp said the EuropeanPatent Office allowed and intends to grant the company a patentfor pharmaceutical and veterinary preparations of geneticallyengineered Interleukin-2 analog.    Interleuken-2 is an immune modulating protein currentlyundergoing clinical trials in the United States and Europe forpotential use in the treatment of various forms of cancer,Cetus said.    It said the allowance is the first step in the patentprocess.    Following allowance, the patent is published for oppositionand a nine-month period begins during which interested partieshave an opportunity to voice any objections to the patent,Cetus said. Reuter&#3;